Cartesian Therapeutics Competitors and Similar CompaniesClear all

Cartesian Therapeutics's competitors and similar companies include Seed Health, UCB, Ipsen and Vertex Pharmaceuticals.

	Cartesian Therapeutics Cartesian Therapeutics (formerly Selecta Biosciences) is a clinical-stage biopharmaceutical company advancing a differentiated product pipeline to modulate the immune system.	Seed Health Seed Health is a microbial sciences company developing applications of bacteria to impact human and environmental health.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Ipsen Ipsen is a biopharmaceutical company.	Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines.
Founding Date	Founding Date 2007	Founding Date 2016	Founding Date 1928	Founding Date 1929	Founding Date 1989
Type	Type Public	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development supplements	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Watertown, US HQ	Locations Venice, US HQ	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more	Locations Boston, US HQ St Leonards, AU Wien, AT Bruxelles, BE São Paulo, BR Toronto, CA Praha, CZ see more
Employees	Employees 15	Employees 234	Employees 9,052	Employees 5,358	Employees 5,40013% increase
Valuation ($)	Valuation ($) 536.3 m	Valuation ($) N/A	Valuation ($) 34.3 b	Valuation ($) 10.2 b	Valuation ($) 121.4 b
Financial
Revenue (est.)	Revenue (est.) $2.8m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) €3.7b (FY, 2025)	Revenue (est.) $12b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods €1.4b (FY, 2025)	Cost of goods €659.1m (FY, 2025)	Cost of goods $1.7b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit €7.2b (FY, 2025)	Gross profit €3.3b (FY, 2025)	Gross profit $10.4b (FY, 2025)
Net income	Net income ($130.3m) (FY, 2025)	Net income N/A	Net income €1.6b (FY, 2025)	Net income €445.1m (FY, 2025)	Net income N/A
Funding
Total funding raised	Total funding raised $ 167.7m	Total funding raised $ 40m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 2.4m